ReviewFrontiers in bioengineering and biotechnology2020
Modifying and Integrating
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- In vitro approaches to assess respiratory toxicity from volatile organic compounds: an in-depth review.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- The Advanced Integrated Respiratory (AIR) Model: Integration of Air-Liquid Interface Cell Cultures within a Human Airway Model for Inhalation Toxicology.Pharmaceutical research · 2026Article
- The isolated perfused lung: a bridge between in vitro and in vivo studies of inhaled medicinal products.AAPS PharmSciTech · 2026Review
- Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.Advanced healthcare materials · 2026Review
- Generation of a human vascularized 3D airway model replicating native mucosal heterogeneity.Frontiers in bioengineering and biotechnology · 2026Article
- Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro.Antioxidants (Basel, Switzerland) · 2025Article
- Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.Molecular therapy. Nucleic acids · 2024Article
- Aerosol of Enoximone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex, Biopharmaceutical Evidence for ARDS Applicability.Pharmaceutics · 2024Article
- Recreating chronic respiratory infectionsEuropean respiratory review : an official journal of the European Respiratory Society · 2024Review
- Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.International journal of molecular sciences · 2024Review
- Sensitivity Analysis and Uncertainty Quantification of Nanoparticle Deposition from Tongue Morphological Variations.Life (Basel, Switzerland) · 2024Article
- Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study.Materials today. Bio · 2024Review
- The promise of Synovial Joint-on-a-Chip in rheumatoid arthritis.Frontiers in immunology · 2024Review
- Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods.Pharmaceutics · 2023Review
- Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery.Polymers · 2023Review
- Basic Science Perspective on Engineering and Modeling the Large Airways.Advances in experimental medicine and biology · 2023Article
- A multiplex inhalation platform to modelFrontiers in pharmacology · 2023Article
- Lung Organoids for Hazard Assessment of Nanomaterials.International journal of molecular sciences · 2022Article
- Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the past 50 years, the route of inhalation has been utilized to administer therapies to treat a variety of respiratory and pulmonary diseases. When compared with other drug administration routes, inhalation offers a targeted, non-invasive approach to deliver rapid onset of drug action to the lung, minimizing systemic drug exposure and subsequent side effects. However, despite advances in inhaled therapies, there is still a need to improve the preclinical screening and the efficacy of inhaled therapeutics. Innovative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.